Octapharma to Build $1.5B Manufacturing Site in South Carolina

Editor’s Take: Whether based in the U.S. or globally, companies continue to seek opportunities to grow their business stateside.

Octapharma, a privately owned and independent plasma fractionator, has announced plans to establish its first-ever United States-based manufacturing and production site at the Palmetto Research Park in Rock Hill, South Carolina.

The $1.5 billion project is expected to bring 1,500 full-time jobs to South Carolina. Once operational, it will produce critical, life-saving medicines from Octapharma’s portfolio of plasma-derived therapies, strengthening the domestic biomedical supply chain while also complementing the company’s global manufacturing capabilities. Octapharma’s Rock Hill site will also produce bleeding management and trauma care products for national security and emergency preparedness needs.

Rock Hill was chosen for its proven infrastructure for advanced manufacturing, access to deep-water ports and proximity to major logistics networks. Additionally, South Carolina’s strong pipeline of biomedical and life sciences talent, supported by top-tier technical colleges and universities, will provide the workforce needed to support clean, efficient biopharmaceutical manufacturing at scale.

“We expect significant future growth, driven by our existing life-saving therapies and a strong pipeline of new products,” said Wolfgang Marguerre, CEO and Chairman, Octapharma. “Our manufacturing capacity must evolve to support this ambition, and our U.S. manufacturing facility will be an important milestone. From a U.S. national security perspective, having the ability to produce and supply our therapies domestically is invaluable.”